Treatment
Treatment guidelines
The focused update to the 2021 ESC HF guidelines recommends addressing iron deficiency when managing HF2
The update includes higher levels of recommendation and addresses a broader patient group for the management of iron deficiency in HF patients with compromised heart function2
Per the focused update to the 2021 ESC HF guidelines, ferric carboxymaltose should be considered for the treatment of symptomatic HFrEF and HFmrEF patients to:2
- Alleviate HF symptoms and improve QoL
- Reduce the risk of HF hospitalisation (regardless of hospitalisation history)
Recommendations from the focused update to the 2021 ESC HF guidelines
Recommendation – Class I/Level of evidence A2
Intravenous iron supplementation is recommended in symptomatic patients with HFrEF and HFmrEF, and iron deficiency, to alleviate HF symptoms and improve quality of life
Recommendation – Class IIa/Level of evidence A2
Intravenous iron supplementation with ferric carboxymaltose or ferric derisomaltose should be considered in symptomatic patients with HFrEF and HFmrEF, and iron deficiency, to reduce the risk of HF hospitalization
References & footnotes
Abbreviations
ESC, European Society of Cardiology; HF, heart failure; HFmrEF, heart failure with mildly reduced ejection fraction; HFrEF, heart failure with reduced ejection fraction; ID, iron deficiency; IV, intravenous; QoL, quality of life.
References
- Ferinject UAE SmPC. Ferinject KSA SmPC.
- McDonagh TA et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023;44(37):3627–39.
- McDonagh TA et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42(36):3599–726.
A complete copy of the cited publications may be requested from CSL in your country.
CSL is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency and nephrology. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).
For more information about CSL, visit www.cslvifor.com.
This website is intended for healthcare professionals only.
This is an international campaign for Ferinject®. Please contact your local CSL representative for the latest information specific to your country.